This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Anacor Pharmaceuticals Is Not for Everyone

NEW YORK (TheStreet) -- I have been talking about, writing about and, most important, investing in stocks for my clients and myself for a long time. You do not have to be a scientist or doctor to invest in scientific or medical progress.

Of the nearly 3,800 stocks I cover in my database, most do not get white-hot overnight. Neither do they lose all their value overnight.

So I look for industries first, then companies within those industries when I am selecting investments. I use the database that I created to select the Best Stocks Now.

That is how I found Anacor Pharmaceuticals (ANAC - Get Report).

Data from Best Stocks Now App

Must Read: Jim Cramer's 6 Stocks in 60 Seconds: CVS MU URI NWN EMC AVP (Update 1)

I didn't hear about ANAC from a televised talking head. Nor did I read about it in the Wall Street Journal or Barron's. I found it while scouring the database that I created.

ANAC is in the atopic dermatitis business. Eczema. One of its products is getting some good results and some even say it could be a new standard of treatment for this disease. But just because something is a good company in a good industry with a good even great product, it does not necessarily mean it is a good stock.

ANAC became public in 2010 at $5 per share. I noticed it three months ago when it hit #23 based on my proprietary grading system. Looking at the chart, we see it has done a powerful saucer pattern from April until Mid-August of this year when ANAC broke out and rose up the ranks in my database.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ANAC $58.59 -4.47%
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs